Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIPA: Plasma-Lyte vs 0.9% Saline in Hip Replacement Surgery
NCT02528448Phase 4Unknown
- Sponsor
- Regionshospitalet Holstebro
- Start
- Mar 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of plasma-lyte in nephrotoxicity, sponsored by Regionshospitalet Holstebro. Primary endpoint: Urinary excretion of Neutrophil gelatinase-associated lipocalin at 2 days. Status: unknown.
02
Drugs
plasma-lyte
03
Conditions
nephrotoxicity
Beyond the preview
Go deeper on NCT02528448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528448.